Jones Trading initiated coverage of Seaport Therapeutics on Tuesday with a buy recommendation and a $32 price target, valuing the NASDAQ-listed biotech at a 29% premium to its closing price of $24.83.
The firm’s analyst Justin Walsh highlighted Seaport’s Glyph platform, a proprietary lymphatic-targeted prodrug system designed to overcome limitations of existing neuropsychiatric treatments. The platform addresses issues such as low bioavailability, extensive first-pass metabolism, pharmacokinetic variability, tolerability concerns, and intellectual property constraints.
Jones Trading’s price target compares with a broader analyst range of $30 to $50, including H.C. Wainwright’s $50 target and Stifel’s $30 target. The firm’s valuation implies a 29% upside from the current share price, though it remains below the 52-week high of $26.47.
Seaport’s lead asset, GlyphAllo (SPT-300), is a prodrug for major depressive disorder, with Phase 2b clinical trial results from the BUOY-1 study expected in the first half of 2027. The company’s second asset, GlyphAgo (SPT-320), targets anxiety and has completed a seven-day Phase 1 trial demonstrating therapeutic exposures without liver-related adverse events.
The Glyph platform’s mechanism leverages clinically validated molecules previously constrained by delivery challenges. Seaport Therapeutics describes itself as a clinical-stage biotechnology company focused on developing treatments for depression, anxiety, and other neuropsychiatric disorders.
InvestingPro’s financial health assessment rates Seaport as "GREAT" despite the company not yet being profitable. The platform’s Fair Value analysis, however, suggests the stock may be overvalued at current levels.
